The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2

Biochemical Pharmacology

Volumn 77, Issue 10, 2009, Pages 1586-1592

  Harrison, Luke R E ^a   Ottley, Christopher J ^b   Pearson, D Graham ^b   Roche, Céline ^a   Wedge, Stephen R ^c   Dolan, M Eileen ^d   Newell, David R ^a   Tilby, Michael J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cisplatin; Kinase inhibitor; Melphalan; NU2058; Potentiation

Indexed keywords

6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE; CISPLATIN; CYCLIN DEPENDENT KINASE 2; HYDROXYMELPHALAN; MELPHALAN; NU 6230; PHOSPHOTRANSFERASE INHIBITOR; PURINE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GUANINE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL FREE SYSTEM; CLONOGENIC ASSAY; DNA ADDUCT; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IC 50; IONIZING RADIATION; PRIORITY JOURNAL; STRUCTURAL HOMOLOGY; CELL SURVIVAL; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE 2; DNA ADDUCTS; DRUG SYNERGISM; GUANINE; HUMANS; PROTEIN KINASE INHIBITORS; TUMOR STEM CELL ASSAY;

EID: 64449086453     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.02.018     Document Type: Article

References (29)

1. Einhorn L.H. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 99 (2002) 4592-4595
2. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4 (2005) 307-320
3. Safaei R., Holzer A.K., Katano K., Samimi G., and Howell S.B. The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 98 (2004) 1607-1613
4. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53 (2005) 13-23
5. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
6. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33 (2007) 9-23
7. Boulikas T., and Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 10 (2003) 1663-1682 (Review)
8. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 (1996) 4881-4886
9. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
10. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
11. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 (2006) 1770-1783
12. Drees M., Dengler W.A., Roth T., Labonte H., Mayo J., Malspeis L., et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3 (1997) 273-279
13. Byrd J.C., Lin T.S., Dalton J.T., Wu D., Phelps M.A., Fischer B., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
14. Shapiro G.I., Koestner D.A., Matranga C.B., and Rollins B.J. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 5 (1999) 2925-2938
15. Bible K.C., and Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57 (1997) 3375-3380
16. Arris C.E., Boyle F.T., Calvert A.H., Curtin N.J., Endicott J.A., Garman E.F., et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 43 (2000) 2797-2804
17. Fishel M.L., Newell D.R., Griffin R.J., Davison R., Wang L.Z., Curtin N.J., et al. Effect of cell cycle inhibition on cisplatin-induced cytotoxicity. J Pharmacol Exp Ther 312 (2005) 206-213
18. Tilby M.J., Newell D.R., Viner C., Selby P.J., and Dean C.J. Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. Eur J Cancer 29A (1993) 681-686
19. Davies T.G., Bentley J., Arris C.E., Boyle F.T., Curtin N.J., Endicott J.A., et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 9 (2002) 745-749
20. Fishel M.L., Delaney S.M., Friesen L.D., Hansen R.J., Zuhowski E.G., Moschel R.C., et al. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther 2 (2003) 633-640
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
22. Meczes E.L., Azim-Araghi A., Ottley C.J., Pearson D.G., and Tilby M.J. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA. Biochem Pharmacol 70 (2005) 1717-1725
23. Tilby M.J., Styles J.M., and Dean C.J. Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. Cancer Res 47 (1987) 1542-1546
24. Zarkowska T., and Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272 (1997) 12738-12746
25. Gould K.A., Nixon C., and Tilby M.J. p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts. Mol Pharmacol 66 (2004) 1301-1309
26. Fichtinger-Schepman A.M., Lohman P.H., and Reedijk J. Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum(II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res 10 (1982) 5345-5356
27. Knox R.J., Friedlos F., Lydall D.A., and Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46 (1986) 1972-1979
28. Roberts J.J., and Friedlos F. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol Ther 34 (1987) 215-246
29. Wang D., and Lippard S.J. Cisplatin-induced post-translational modification of histones H3 and H4. J Biol Chem 279 (2004) 20622-20625